Lactovac Suspension for injection

Not authorised

- Bovine rotavirus A, strain 1005/78, Inactivated
- Bovine rotavirus A, strain Holland, Inactivated
- Bovine coronavirus, strain 800, Inactivated
- Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

Product identification

Medicine name:
Lactovac Suspension for injection

Active substance:
Bovine rotavirus A, strain 1005/78, Inactivated

Bovine rotavirus A, strain Holland, Inactivated

Bovine coronavirus, strain 800, Inactivated

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

Target species:
Cattle

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Bovine rotavirus A, strain 1005/78, Inactivated
1.00 relative potency / 1.00 Dose

Bovine rotavirus A, strain Holland, Inactivated
1.00 relative potency / 1.00 Dose

Bovine coronavirus, strain 800, Inactivated
1.00 relative potency / 1.00 Dose

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated
1.00 relative potency / 1.00 Dose

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Cattle**
  - Meat and offal. 0 day
  - Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Surrendered

Authorised in:

Belgium

Package description:

Type I glass vial containing 5 ml. The glass vial is closed with a type I rubber stopper, sealed with an aluminium crimp cap. Cardboard box with 10 glass vials of 1 dose (5 ml).
Type I glass vial containing 25 ml. The glass vial is closed with a type I rubber stopper, sealed with an aluminium crimp cap. Cardboard box with 1 glass vial of 5 doses (25 ml).

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
16/07/2020

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V567084

Date of authorisation status change:
3/06/2022

Reference member state:
Ireland

Procedure number:
IE/V/0417/001

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.